Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II photodynamic therapy with talaporfin sodium for cT1–T2 esophageal cancer unsuitable for standard treatment
jRCTs032240616Phase 2Recruiting
- Sponsor
- Yokohama City University
- Start
- Jan 2025
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talaporfin sodium in esophageal cancer, sponsored by Yokohama City University. Primary endpoint: Local tumor control rate at 24 weeks. Started Jan 2025; status: recruiting.
02
Drugs
talaporfin sodium
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCTs032240616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs032240616.